Lupin Launches Bromfenac Ophthalmic Solution 0.075% for Post-Cataract Care

Lupin launched Bromfenac Ophthalmic Solution, 0.075%, post FDA approval. Treats post-cataract inflammation & pain.

Global pharmaceutical giant Lupin Limited has launched Bromfenac Ophthalmic Solution, 0.075%, subsequent to obtaining approval from the United States Food and Drug Administration (US FDA).

This solution serves as the generic counterpart to BromSite Ophthalmic Solution, 0.075%, produced by Sun Pharmaceutical Industries Limited. Its primary indications include the treatment of postoperative inflammation and the prevention of ocular pain among patients undergoing cataract surgery.

Bromfenac Solution: Advancing Post-Cataract Recovery

Bromfenac Ophthalmic Solution, also known as BromSite, is a medication used to help with inflammation and pain after cataract surgery. It contains an active ingredient called bromfenac, which is a type of medicine known as a nonsteroidal anti-inflammatory drug (NSAID).

How does it work?

Bromfenac is the key ingredient that helps reduce inflammation and pain in the eye. It's specially designed to penetrate the cornea, which is the clear outer layer of the eye.

Once applied, bromfenac is broken down into a substance called amfenac by enzymes in the eye. This amfenac is what actually works to reduce inflammation. It spreads across the cornea, targeting the areas that need relief from swelling and discomfort.

In a nutshell, BromSite contains bromfenac, a potent anti-inflammatory drug, which is engineered to stay on the eye's surface for an extended period. This helps effectively reduce inflammation and pain following cataract surgery.

Bromfenac Ophthalmic Solution, 0.075% (RLD BromSite), recorded approximately $15 million in estimated annual sales in the US as of IQVIA MAT December 2023. This introduction signifies Lupin Limitged's commitment to providing effective solutions within the ophthalmic pharmaceutical realm.

Lupin is an innovation-driven global pharmaceutical company headquartered in Mumbai, India. The company specializes in the development and commercialisation of a wide range of branded and generic formulations, biotechnology products, and APIs (Active Pharmaceutical Ingredients).

Lupin's Recent Digital Health Initiatives

Earlier this year, in January, Lupin Digital Health partnered with the American College of Cardiology (ACC) to launch the first-ever Digital Therapeutics Certificate for cardiologists. This certificate acknowledges cardiologists who embrace Lupin's Remote Cardiac Rehab and Digital Heart Failure clinic solutions, underscoring their commitment to innovation and patient-centric healthcare. The collaboration was aimed at enhancing the quality of care and optimizing outcomes, all within the convenience of patients' homes.

In December, last year, Lupin Limited obtained approval from the United States Food and Drug Administration (USFDA) for its Loteprednol Etabonate Ophthalmic Suspension, 0.2%, a generic version of Alrex. This medication addresses seasonal allergic conjunctivitis and is estimated to generate annual sales of USD 29.1 million in the US. Lupin's approval enables it to market the generic equivalent of Alrex Ophthalmic Suspension, 0.2%, initially developed by Bausch & Lomb Inc.

In October, last year, Lupin Limited launched Humrahi, a patient support program focused on diabetes management, emphasizing adherence, behavior modification, and transformation. India faced the highest global burden of diabetes, with 77 million individuals affected and projected to rise to 134 million by 2045. Diabetes posed various complications, including heart disease, stroke, kidney issues, nerve damage, and vision impairment. The surge in diabetes, pre-diabetes, and hypertension cases in the Asian subcontinent underscored the urgent need for effective disease management solutions.